Jump to content

Long

Senior Member
  • Content Count

    4643
  • Joined

  • Last visited

  • Days Won

    8

Long last won the day on May 18 2019

Long had the most liked content!

Community Reputation

3774 Is a bearer of wisdom

About Long

  • Rank
    Special Agent

Contact Methods

  • Discord
    =Long*#7196

Profile Information

  • Alias
    =F|A=Long*
  • Admin
    16
  • Server
    Jay1
  • Gender
    Male
  • Interests
    ~ Fußball (BFC Dynamo)
    ~ Bier
    ~ & Bockwurst mit Senf
  • TB
    4701496
  • Location
    [East]Germany

Notes

  • T-M
    5-4

Recent Profile Visitors

53579 profile views
  1. Long

    Greeting!

    Hallo & Welcome
  2. National Center for Biotechnology Information Potential False-Positive Rate Among the 'Asymptomatic Infected Individuals' in Close Contacts of COVID-19 Patients Results: When the infection rate of the close contacts and the sensitivity and specificity of reported results were taken as the point estimates, the positive predictive value of the active screening was only 19.67%, in contrast, the false-positive rate of positive results was 80.33%. The multivariate-probabilistic sensitivity analysis results supported the base-case findings, with a 75% probability for the false-positive rate of positive results over 47%. Conclusions: In the close contacts of COVID-19 patients, nearly half or even more of the 'asymptomatic infected individuals' reported in the active nucleic acid test screening might be false positives. https://pubmed.ncbi.nlm.nih.gov/32133832/?fbclid=IwAR1x58i9MUS16isOtdzAOJHr1TZNpVz4kw-6S5mtyRG_MUg3XVK_RajavAI
  3. Event 201 The Johns Hopkins Center for Health Security in partnership with the World Economic Forum and the Bill and Melinda Gates Foundation hosted Event 201, a high-level pandemic exercise on October 18, 2019, in New York, NY. The exercise illustrated areas where public/private partnerships will be necessary during the response to a severe pandemic in order to diminish large-scale economic and societal consequences. http://www.centerforhealthsecurity.org/event201/index.html The Event 201 scenario Event 201 simulates an outbreak of a novel zoonotic coronavirus transmitted from bats to pigs to people that eventually becomes efficiently transmissible from person to person, leading to a severe pandemic. The pathogen and the disease it causes are modeled largely on SARS, but it is more transmissible in the community setting by people with mild symptoms. The disease starts in pig farms in Brazil, quietly and slowly at first, but then it starts to spread more rapidly in healthcare settings. When it starts to spread efficiently from person to person in the low-income, densely packed neighborhoods of some of the megacities in South America, the epidemic explodes. It is first exported by air travel to Portugal, the United States, and China and then to many other countries. Although at first some countries are able to control it, it continues to spread and be reintroduced, and eventually no country can maintain control. http://www.centerforhealthsecurity.org/event201/scenario.html Statement about nCoV and our pandemic exercise In October 2019, the Johns Hopkins Center for Health Security hosted a pandemic tabletop exercise called Event 201 with partners, the World Economic Forum and the Bill & Melinda Gates Foundation. Recently, the Center for Health Security has received questions about whether that pandemic exercise predicted the current novel coronavirus outbreak in China. To be clear, the Center for Health Security and partners did not make a prediction during our tabletop exercise. For the scenario, we modeled a fictional coronavirus pandemic, but we explicitly stated that it was not a prediction. Instead, the exercise served to highlight preparedness and response challenges that would likely arise in a very severe pandemic. We are not now predicting that the nCoV-2019 outbreak will kill 65 million people. Although our tabletop exercise included a mock novel coronavirus, the inputs we used for modeling the potential impact of that fictional virus are not similar to nCoV-2019. http://www.centerforhealthsecurity.org/newsroom/center-news/2020-01-24-Statement-of-Clarification-Event201.html http://www.centerforhealthsecurity.org/event201/event201-resources/CAPS-fact-sheet-191009.pdf
  4. Moderna’s Work on a Potential Vaccine Against COVID-19 (mRNA-1273) Notable about the Fauci-Gates Moderna coronavirus vaccine, mRNA-1273, is that it has been rolled out in a matter of weeks, not years, and on February 24 went directly to Fauci’s NIH for tests on human guinea pigs, not on mice as normal. Moderna’s chief medical adviser, Tal Zaks, argued, “I don’t think proving this in an animal model is on the critical path to getting this to a clinical trial.” Another notable admission by Moderna on its website is the legal disclaimer, “Special Note Regarding Forward-Looking Statements: …These risks, uncertainties, and other factors include, among others: … the fact that there has never been a commercial product utilizing mRNA technology approved for use.” In other words, completely unproven for human health and safety. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s development of a potential vaccine against the novel Coronavirus, the conduct and timing of the Phase I study of mRNA-1273, the planning, conduct and timing of a potential Phase 2 and any subsequent trials of mRNA-1273, and potential manufacturing capabilities. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this summary and FAQ are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this summary and FAQ in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof. INOVIO Pharmaceuticals, Inc.-INO-4800, a DNA vaccine for COVID-19 Inovio recently completed the preclinical testing of a DNA-based vaccine called INO-4800. And clinical trials are expected to begin in April with patients in the U.S., as well as China and South Korea. The company expects to have first trial results in the fall and have one million vaccines doses ready by the end of the year. This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our expectations regarding our research and development programs, as well as commercialization activities, including the planned initiation and conduct of clinical trials, the availability and timing of data from those trials and our commercialization strategy and tactics. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2018, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. If that is to the good of mankind or grounds to be worried, time will tell. https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19 http://ir.inovio.com/news-and-media/news/press-release-details/2020/INOVIO-Receives-New-5-Million-Grant-to-Accelerate-Scale-Up-of-Smart-Delivery-Device-for-Its-COVID-19-Vaccine/default.aspx https://www.globalresearch.ca/coronavirus-gates-foundation/5706842

About Us

We are glad you decided to stop by our website and servers. At Fearless Assassins Gaming Community (=F|A=) we strive to bring you the best gaming experience possible. With helpful admins, custom maps and good server regulars your gaming experience should be grand! We love to have fun by playing online games especially W:ET, Call of Duty Series, Counter Strike: Series, Minecraft, Insurgency, DOI, TF2 & Battlefield Series and if you like to do same then join us! Here, you can make worldwide friends while enjoying the game. Anyone from any race and country speaking any language can join our Discord and gaming servers. We have clan members from US, Canada, Europe, Sri Lanka, India, Japan, Australia, Brazil, UK, Austria, Poland, Finland and many other countries. It doesn't matter how much good you are in the game or how much good English you speak. We believe in making new friends from all over the world. If you want to have fun and want to make new friends join up our gaming servers and our VoIP servers any day and at any time. .

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.